AIM ImmunoTech (NYSE:AIM) Shares Down 1.9% – Here’s What Happened

AIM ImmunoTech Inc. (NYSE:AIM) was down 1.9% during mid-day trading on Tuesday . The company traded as low as $0.13 and last traded at $0.14. Approximately 193,467 shares were traded during trading, a decline of 62% from the average daily volume of 513,785 shares. The stock had previously closed at $0.14.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets lowered their target price on shares of AIM ImmunoTech from $5.00 to $4.50 and set a “buy” rating for the company in a report on Tuesday, December 10th.

AIM ImmunoTech Price Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a market capitalization of $8.79 million, a P/E ratio of -0.27 and a beta of 0.41. The stock has a 50-day simple moving average of $0.15 and a 200 day simple moving average of $0.21.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).